Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Brundage

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
European Journal of Drug Metabolism and Pharmacokinetics|November 30, 2018
A Gallbladder-Based Enterohepatic Circulation Model for Pharmacokinetic StudiesMalek Okour, Richard C Brundage
The AAPS Journal|May 21, 2020
Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysisAli A Alhadab, Richard C Brundage
Clinical Pharmacology and Therapeutics|March 5, 2020
Physiologically-Based Pharmacokinetic Model of Sertraline in Human to Predict Clinical Relevance of Concentrations at Target TissuesAli A Alhadab, Richard C Brundage
Journal of Pharmacokinetics and Pharmacodynamics|January 8, 2023
Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modelingMutaz M Jaber, Richard C Brundage
CPT: Pharmacometrics & Systems Pharmacology|May 5, 2021
Evaluation of bias in weighted residual calculations when handling below the limit of quantification data using Beal's M3 methodMutaz M Jaber, Shen Cheng, Richard C Brundage
Journal of Pharmacokinetics and Pharmacodynamics|October 27, 2007
Impact of censoring data below an arbitrary quantification limit on structural model misspecificationWonkyung Byon, Courtney V Fletcher, Richard C Brundage
Journal of Pharmacokinetics and Pharmacodynamics|October 21, 2006
Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotypeNitin Kaila, Robert J Straka, Richard C Brundage
CNS Drugs|August 3, 2002
Clinical implications of CNS penetration of antiretroviral drugsHeather E Wynn, Richard C Brundage, Courtney V Fletcher
Antimicrobial Agents and Chemotherapy|January 24, 2018
Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer PatientsAli A Alhadab, Mariam A Ahmed, Richard C Brundage
Antimicrobial Agents and Chemotherapy|October 23, 2013
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected childrenAhmed Hamed Salem, Courtney V Fletcher, Richard C Brundage
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
European Journal of Drug Metabolism and Pharmacokinetics|November 30, 2018
A Gallbladder-Based Enterohepatic Circulation Model for Pharmacokinetic StudiesMalek Okour, Richard C Brundage
The AAPS Journal|May 21, 2020
Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysisAli A Alhadab, Richard C Brundage
Clinical Pharmacology and Therapeutics|March 5, 2020
Physiologically-Based Pharmacokinetic Model of Sertraline in Human to Predict Clinical Relevance of Concentrations at Target TissuesAli A Alhadab, Richard C Brundage
Journal of Pharmacokinetics and Pharmacodynamics|January 8, 2023
Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modelingMutaz M Jaber, Richard C Brundage
CPT: Pharmacometrics & Systems Pharmacology|May 5, 2021
Evaluation of bias in weighted residual calculations when handling below the limit of quantification data using Beal's M3 methodMutaz M Jaber, Shen Cheng, Richard C Brundage
Journal of Pharmacokinetics and Pharmacodynamics|October 27, 2007
Impact of censoring data below an arbitrary quantification limit on structural model misspecificationWonkyung Byon, Courtney V Fletcher, Richard C Brundage
Journal of Pharmacokinetics and Pharmacodynamics|October 21, 2006
Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotypeNitin Kaila, Robert J Straka, Richard C Brundage
CNS Drugs|August 3, 2002
Clinical implications of CNS penetration of antiretroviral drugsHeather E Wynn, Richard C Brundage, Courtney V Fletcher
Antimicrobial Agents and Chemotherapy|January 24, 2018
Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer PatientsAli A Alhadab, Mariam A Ahmed, Richard C Brundage
Antimicrobial Agents and Chemotherapy|October 23, 2013
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected childrenAhmed Hamed Salem, Courtney V Fletcher, Richard C Brundage
Pageof 9